Description: GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Home Page: www.gsk.com
980 Great West Road
Brentford,
TW8 9GS
United Kingdom
Phone:
44 20 8047 5000
Officers
| Name | Title |
|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director |
| Mr. Iain James Mackay | CFO & Exec. Director |
| Ms. Julie Brown | Chief Financial Officer |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer |
| Mr. Tony Wood | Chief Scientific Officer |
| Ms. Sarah Elton-Farr | Head of Investor Relations |
| Mr. James Ford | Sr. VP & Group Gen. Counsel of Legal & Compliance |
| Ms. Sally Jackson | Sr. VP of Global Communications & CEO Office |
| Ms. Diana Conrad | Chief People Officer |
| Mr. David Simon Redfern | Chief Strategy Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 9.7087 |
|---|---|
| Trailing PE: | 13.5385 |
| Price-to-Book MRQ: | 6.4874 |
| Price-to-Sales TTM: | 1.9064 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 90096 |